Profile data is unavailable for this security.
About the company
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
- Revenue in AUD (TTM)0.00
- Net income in AUD-69.02m
- Incorporated1986
- Employees0.00
- LocationImugene LtdSuite 12.01, Level 12, Bligh House,4-6 BSYDNEY 2000AustraliaAUS
- Phone+61 39824-5254
- Fax+61 39822-7735
- Websitehttps://www.imugene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emyria Ltd | 1.39m | -3.14m | 43.55m | -- | -- | 6.22 | -- | 31.23 | -0.0069 | -0.0069 | 0.0031 | 0.0087 | 0.2316 | -- | 40.72 | -- | -52.19 | -82.51 | -69.83 | -106.69 | 1.76 | -17.98 | -225.33 | -355.61 | -- | -22.44 | 0.1037 | -- | -36.68 | 6.60 | 72.57 | -- | -41.45 | -- |
| Entropy Neurodynamics Ltd | 1.59m | -5.33m | 50.05m | -- | -- | 7.72 | -- | 31.53 | -0.0043 | -0.0043 | 0.0012 | 0.0041 | 0.2249 | -- | 0.763 | -- | -75.55 | -- | -92.06 | -- | -- | -- | -335.91 | -- | -- | -100.79 | 0.00 | -- | -- | -10.25 | -- | -- | -26.73 | -- |
| Syntara Ltd | 7.48m | -12.26m | 52.26m | 107.00 | -- | 3.25 | -- | 6.99 | -0.0084 | -0.0054 | 0.0051 | 0.0099 | 0.4701 | -- | 2.53 | -- | -77.03 | -36.39 | -116.54 | -50.26 | -- | -- | -163.86 | -78.37 | -- | -953.38 | 0.0052 | -- | 37.80 | -9.83 | 10.31 | -- | -- | -- |
| Clever Culture Systems Ltd | 6.52m | 1.68m | 63.14m | 17.00 | 37.18 | 9.08 | 33.07 | 9.68 | 0.0008 | 0.0008 | 0.0031 | 0.0032 | 0.6975 | 0.9829 | 6.37 | -- | 18.01 | -36.73 | 22.73 | -42.00 | 77.05 | -- | 25.82 | -281.21 | 1.63 | -- | 0.2653 | -- | 397.86 | 30.08 | 145.03 | -- | 24.71 | -- |
| Amplia Therapeutics Ltd | 5.01m | -7.93m | 64.13m | 1.00 | -- | 1.49 | -- | 12.81 | -0.0204 | -0.0204 | 0.0128 | 0.0837 | 0.1705 | -- | 1.28 | -- | -27.01 | -27.37 | -28.31 | -30.38 | -- | -- | -158.46 | -180.53 | -- | -- | 0.0088 | -- | -15.01 | 156.11 | -45.93 | -- | -- | -- |
| Proteomics International LaboratoriesLtd | 3.31m | -8.11m | 65.25m | -- | -- | 4.90 | -- | 19.70 | -0.0605 | -0.0605 | 0.0247 | 0.0805 | 0.2582 | -- | 12.02 | -- | -63.57 | -63.62 | -68.88 | -71.91 | -- | -- | -246.18 | -222.10 | -- | -- | 0.021 | -- | 1.34 | 15.81 | -27.27 | -- | -54.88 | -- |
| Prescient Therapeutics Ltd | 225.61k | -7.32m | 68.35m | 3.00 | -- | 4.60 | -- | 302.95 | -0.0091 | -0.0091 | 0.0003 | 0.0141 | 0.0129 | -- | 0.9582 | -- | -41.90 | -31.70 | -49.69 | -34.33 | -- | -- | -3,245.66 | -2,146.75 | -- | -590.48 | 0.00 | -- | -67.19 | 26.24 | 11.11 | -- | -- | -- |
| Rhythm Biosciences Ltd | 3.33m | -3.83m | 68.68m | -- | -- | 92.39 | -- | 20.65 | -0.0134 | -0.0134 | 0.0124 | 0.0023 | 1.53 | 98.79 | 67.11 | -- | -176.04 | -146.24 | -469.96 | -197.40 | -10.44 | 22.48 | -115.14 | -287.42 | 0.8046 | -53.89 | 0.6266 | -- | 90.87 | 135.14 | 44.15 | -- | -12.61 | -- |
| Imugene Ltd | 0.00 | -69.02m | 81.99m | 0.00 | -- | 1.24 | -- | -- | -0.3161 | -0.3161 | 0.00 | 0.205 | 0.00 | -- | -- | -- | -58.75 | -48.72 | -75.21 | -53.73 | -- | -- | -- | -- | -- | -- | 0.1913 | -- | -- | -- | 53.89 | -- | 38.40 | -- |
| Alterity Therapeutics Ltd | 446.29k | -12.15m | 87.00m | 9.00 | -- | 1.72 | -- | 194.95 | -0.002 | -0.002 | 0.00007 | 0.0047 | 0.0137 | -- | 5,578.63 | 49,587.78 | -37.23 | -49.00 | -43.12 | -57.35 | -- | -- | -2,721.96 | -9,708.51 | -- | -211.82 | 0.0037 | -- | 66.27 | 91.97 | 36.48 | -- | -- | -- |
| Cynata Therapeutics Ltd | 227.70k | -9.39m | 87.86m | 0.00 | -- | 13.98 | -- | 385.85 | -0.0453 | -0.0453 | 0.0011 | 0.0265 | 0.0292 | -- | 2.16 | -- | -120.50 | -48.36 | -142.29 | -53.09 | -- | -- | -4,124.10 | -576.20 | -- | -1,268.00 | 0.00 | -- | -45.49 | 28.12 | 3.63 | -- | -- | -- |
| LTR Pharma Ltd | 2.10m | -5.59m | 93.62m | -- | -- | 2.96 | -- | 44.50 | -0.0333 | -0.0333 | 0.0126 | 0.1741 | 0.1183 | -- | 8.22 | -- | -31.44 | -- | -32.47 | -- | -- | -- | -265.90 | -- | 45.76 | -62.54 | 0.00 | -- | 4,164.38 | -- | 19.57 | -- | -- | -- |
| Tetratherix Ltd | 1.14m | -9.43m | 100.55m | -- | -- | 6.83 | -- | 88.00 | -0.1873 | -0.1873 | 0.0227 | 0.5414 | 0.0688 | -- | 2.22 | -- | -56.71 | -- | -76.72 | -- | -172.06 | -- | -824.89 | -- | -- | -98.75 | 0.0697 | -- | 32.30 | -- | -269.05 | -- | -- | -- |
| Island Pharmaceuticals Ltd | 58.80k | -3.92m | 103.59m | -- | -- | 12.70 | -- | 1,761.65 | -0.0224 | -0.0224 | 0.0003 | 0.0303 | 0.0117 | -- | 0.1099 | -- | -77.95 | -72.12 | -90.37 | -81.53 | -- | -- | -6,666.91 | -19,239.15 | -- | -162.89 | 0.00 | -- | 1,148.41 | -- | -36.86 | -- | -- | -- |
| Bioxyne Ltd | 28.43m | 4.90m | 107.52m | 16.00 | 20.69 | 8.37 | 18.90 | 3.78 | 0.0023 | 0.0023 | 0.0132 | 0.0057 | 2.16 | 6.30 | 17.06 | -- | 37.31 | -28.17 | 55.76 | -38.16 | 36.32 | 35.97 | 17.24 | -24.14 | 1.90 | -- | 0.1125 | -- | 204.87 | 65.94 | 138.29 | -- | 127.89 | -- |
| Arovella Therapeutics Ltd | 525.53k | -7.51m | 111.71m | 14.00 | -- | 5.51 | -- | 212.57 | -0.0067 | -0.0067 | 0.0005 | 0.0169 | 0.0301 | -- | -- | -- | -43.05 | -75.94 | -47.90 | -90.89 | -- | -- | -1,428.87 | -2,386.13 | -- | -- | 0.00 | -- | 237.44 | -1.82 | 14.14 | -- | 1.23 | -- |
Data as of Feb 16 2026. Currency figures normalised to Imugene Ltd's reporting currency: Australian Dollar AUD
5.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 7.61m | 2.38% |
| Pengana Capital Ltd.as of 31 Oct 2025 | 5.22m | 1.63% |
| Netwealth Investments Ltd.as of 30 Jun 2025 | 3.33m | 1.04% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 18.49k | 0.01% |
| DFA Australia Ltd.as of 31 Dec 2025 | 17.92k | 0.01% |
| The Trustee for Aware Superas of 31 Dec 2024 | 1.42k | 0.00% |
More ▼
Data from 30 Sep 2025 - 02 Feb 2026Source: FactSet Research Systems Inc.
